Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11105MR)

This product GTTS-WQ11105MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11105MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2260MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ13876MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ12785MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ3410MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ9638MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ7283MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ14466MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ7638MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW